VICTOR SANCHEZ: Open Payments
NPI 1801440672 · SAN ANTONIO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,636 in 161 payments from 18 companies in 2025. Trend: 2023 $1,163 · 2024 $2,566 · 2025 $2,636
Food & beverage: $2,636
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 40 | $496 |
| Madrigal Pharmaceuticals | 8 | $279 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 15 | $241 |
| Janssen Biotech, Inc. | 15 | $238 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $213 |
| Ipsen Biopharmaceuticals, Inc | 15 | $197 |
| Gilead Sciences, Inc. | 11 | $175 |
| Lilly USA, LLC | 10 | $165 |
| GENZYME CORPORATION | 5 | $145 |
| Phathom Pharmaceuticals, Inc. | 12 | $141 |
Products named: REZDIFFRA, TREMFYA, XIFAXAN, IQIRVO, RINVOQ, OMVOH, DUPIXENT, LINZESS.
Industry payments across TX — which companies pay providers there.
